E-viri
Recenzirano
Odprti dostop
-
Pahuja, Kanika Bajaj; Nguyen, Thong T.; Jaiswal, Bijay S.; Prabhash, Kumar; Thaker, Tarjani M.; Senger, Kate; Chaudhuri, Subhra; Kljavin, Noelyn M.; Antony, Aju; Phalke, Sameer; Kumar, Prasanna; Mravic, Marco; Stawiski, Eric W.; Vargas, Derek; Durinck, Steffen; Gupta, Ravi; Khanna-Gupta, Arati; Trabucco, Sally E.; Sokol, Ethan S.; Hartmaier, Ryan J.; Singh, Ashish; Chougule, Anuradha; Trivedi, Vaishakhi; Dutt, Amit; Patil, Vijay; Joshi, Amit; Noronha, Vanita; Ziai, James; Banavali, Sripad D.; Ramprasad, Vedam; DeGrado, William F.; Bueno, Raphael; Jura, Natalia; Seshagiri, Somasekar
Cancer cell, 11/2018, Letnik: 34, Številka: 5Journal Article
Deregulated HER2 is a target of many approved cancer drugs. We analyzed 111,176 patient tumors and identified recurrent mutations in HER2 transmembrane domain (TMD) and juxtamembrane domain (JMD) that include G660D, R678Q, E693K, and Q709L. Using a saturation mutagenesis screen and testing of patient-derived mutations we found several activating TMD and JMD mutations. Structural modeling and analysis showed that the TMD/JMD mutations function by improving the active dimer interface or stabilizing an activating conformation. Further, we found that HER2 G660D employed asymmetric kinase dimerization for activation and signaling. Importantly, anti-HER2 antibodies and small-molecule kinase inhibitors blocked the activity of TMD/JMD mutants. Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade. Display omitted •Recurrent HER2 transmembrane/juxtamembrane domain (TMD/JMD) mutations identified•TMD/JMD-activating mutations identified in multiple cancers•Transmembrane HER2 mutant homodimerizes leading to allosteric activation of kinase•TMD/JMD mutants respond to HER2 targeted therapy Pahuja et al. show that recurrent HER2 transmembrane domain and juxtamembrane domain mutations enhance HER2 activity by improving the active dimer interface or stabilizing an activating conformation. Importantly, HER2 inhibiting antibodies and small molecules can block the activity of these mutants.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.